Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
Closed for Enrollment
-
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
Rochester, Minn.
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
-
A Phase III Prospective Randomized Trial of Standard-Fractionation versus Hypo-Fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate
Scottsdale/Phoenix, Ariz.
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are similar or better.
-
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE) (COMPPARE)
Rochester, Minn.,
Mankato, Minn.,
La Crosse, Wis.,
Jacksonville, Fla.,
Eau Claire, Wis.
The purpose of this study is to determine if prostate cancer patients treated with proton therapy as compared to IMRT experience improved QOL (validated EPIC instrument measuring bowel, urinary, and sexual QOL).
-
Evaluation of neuroendocrine differentiation as a potential mechanism of tumor recurrence following radiotherapy
Rochester, Minn.,
Jacksonville, Fla.
This is a pilot study to test a hypothesis that a greater increase in serum chromogranin A (CgA) after a definitive radiotherapy (RT) with or without androgen deprivation therapy (ADT) is associated with a higher risk of prostate cancer recurrence after RT. Serum CgA level is measured before the start of RT and/or the start of neoadjuvant ADT for patients undergoing a definitive RT with or without ADT. CgA is also measured at various pre-defined post-RT time points. The study will analyze the followings: 1. Change in CgA level at various pre-defined post-RT time points from the baseline, 2. Correlation between the extent of post-therapy CgA change and Gleason score of malignancy, 3. Correlation between the extent of post-therapy CgA change and treatment outcome.
-
Prospective Evaluation of Hypofractionation Proton Beam Therapy with Concurrent Treatment of the Prostate and Pelvic Nodes for Clinically Localized, Intermediate or High Risk Prostate Cancer
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the safety and effectiveness of a moderate hypofractionation regimen of proton beam therapy with same time treatment of the prostate, seminal vesicles, and the regional pelvic nodes for patients who have clinically localized, high risk or unfavorable intermediate risk prostate cancer.
.